Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 42, 2007 - Issue 7
Submit an article Journal homepage
160
Views
11
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Productivity improvements in hepatitis C treatment: Impact on efficacy, cost, cost-effectiveness and quality of life

Mathias Lidgren Medical Management Centre, Karolinska Institutet, Stockholm, Sweden; Centre for Health Economics, Stockholm School of Economics, Stockholm, SwedenCorrespondence[email protected]
,
Anna Hollander Division of Infectious Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden
,
Ola Weiland Division of Infectious Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden
&
Bengt Jönsson Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden
Pages 867-877 | Received 20 Jan 2006, Published online: 08 Jul 2009

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Ru Han, Shuyao Liang, Clément François, Samuel Aballea, Emilie Clay & Mondher Toumi. (2021) Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. Journal of Market Access & Health Policy 9:1.
Read now
Antoine C. El Khoury, Carolyn Wallace, William K. Klimack & Homie Razavi. (2012) Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. Journal of Medical Economics 15:5, pages 887-896.
Read now
Magdalena Ydreborg, Ann Söderström, Agneta Håkanson, Åsa Alsiö, Birgitta Arnholm, Petter Malmström, Kristoffer Hellstrand, Johan Westin & Martin Lagging. (2011) Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. Scandinavian Journal of Infectious Diseases 43:6-7, pages 522-527.
Read now

Articles from other publishers (8)

Mehdi Javanbakht, Jesse Fishman, Eoin Moloney, Peter Rydqvist & Amir Ansaripour. (2022) Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis. PharmacoEconomics - Open 7:1, pages 93-110.
Crossref
Peter Lindgren, Sofia Löfvendahl, Gunnar Brådvik, Ola Weiland & Bengt Jönsson. (2021) Value appropriation in hepatitis C. The European Journal of Health Economics 23:6, pages 1059-1070.
Crossref
Ru Han, Clément François & Mondher Toumi. (2020) Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. Applied Health Economics and Health Policy 19:1, pages 29-44.
Crossref
Christian Krauth, Siegbert Rossol, Gustaf Ortsäter, Achim Kautz, Kathrin Krüger, Babette Herder & Jona Theodor Stahmeyer. (2019) Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. BMC Infectious Diseases 19:1.
Crossref
Kee Chan, Mai Ngan Lai, Erik J. Groessl, Amresh D. Hanchate, John B. Wong, Jack A. Clark, Steven M. Asch, Allen L. Gifford & Samuel B. Ho. (2013) Cost Effectiveness of Direct-Acting Antiviral Therapy for Treatment-Naive Patients With Chronic HCV Genotype 1 Infection in the Veterans Health Administration. Clinical Gastroenterology and Hepatology 11:11, pages 1503-1510.
Crossref
Rebecca Townsend, Phil McEwan, Ray Kim & Yong Yuan. (2011) Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C. Value in Health 14:8, pages 1068-1077.
Crossref
Jennifer A. Tan, Tom A. Joseph & Sammy Saab. (2008) Treating hepatitis C in the prison population is cost-saving. Hepatology 48:5, pages 1387-1395.
Crossref
O. Weiland, A. Hollander, L. Mattsson, H. Glaumann, K. Lindahl, R. Schvarcz, G. Lindh, R. Enquist & A. Quist. (2008) Lower‐than‐standard dose peg‐IFN alfa‐2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight‐based ribavirin. Journal of Viral Hepatitis 15:9, pages 641-645.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.